In defense of alternative antihypertensive therapy.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006321:Heart / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D008074:Lipoproteins / Q000097:blood / Q000145:classification; D010349:Patient Compliance; D011788:Quality of Life; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004232:Diuretics; D008074:Lipoproteins; D014665:Vasodilator Agents; D002784:Cholesterol